Arcellx's 15-minute chart shows MACD Death Cross, KDJ Death Cross signals.

Arcellx's 15-minute chart exhibited a MACD Death Cross and KDJ Death Cross on July 17, 2025, at 14:15. This suggests that the stock's price has the potential to continue declining, with a shift in momentum towards the downside and a possible further decrease in value.

Arcellx, Inc. (NASDAQ: ACLX) has been making significant strides in the development of its lead CAR-T cell therapy, anitocabtagene Autoleucel (anito-cel), for the treatment of patients with relapsed/refractory multiple myeloma (r/r MM). The company's recent progress in its phase 3 iMMagine-3 trial, which is evaluating anito-cel in treating MM patients with 1 to 3 prior lines of therapy, has raised investor interest. However, the stock's recent chart patterns suggest a potential downturn.

The iMMagine-3 trial, which is currently enrolling patients, aims to assess the efficacy of anito-cel in treating r/r MM patients who have failed previous therapies. The trial's primary endpoint is progression-free survival (PFS), but the company has recently been allowed to include another dual primary efficacy endpoint measure of minimal residual disease (MRD) negativity into the protocol [1].

Arcellx's stock exhibited a MACD Death Cross and KDJ Death Cross on July 17, 2025, at 14:15, suggesting a potential shift in momentum towards the downside. This technical indicator typically signals a change in trend, potentially indicating a further decrease in value [2].

The company's recent positive data from the pivotal phase 2 iMMagine-1 study, which had an overall response rate (ORR) of 97% and a complete response (CR) rate of 68%, bodes well for the ongoing phase 3 trial. However, the success of the phase 3 trial is not guaranteed, and there are several risks to consider. The trial's success depends on anito-cel performing better than current standard of care (SOC) therapies, which may work in treating these patients. Additionally, the FDA's acceptance of the company's Biologics License Application (BLA) for anito-cel is not assured, and the manufacturing process may pose challenges [1].

Arcellx's strong cash position, with $565.2 million as of March 31, 2025, provides a solid foundation for its operations. However, the company's cash runway may not be sufficient to cover all potential expenses if the trial fails or faces regulatory hurdles [1].

In conclusion, while Arcellx's progress in developing anito-cel is promising, the stock's recent chart patterns suggest a potential downturn. Investors should closely monitor the company's trial results and regulatory filings, as well as the stock's technical indicators, to make informed investment decisions.

References:
[1] https://seekingalpha.com/article/4801456-arcellx-anito-cel-with-d-domain-differentiation-looks-to-capture-rr-mm-market
[2] https://www.investopedia.com/terms/m/macd.asp